Skip to main content
Sunshine Biopharma Inc. logo

Sunshine Biopharma Inc. — Investor Relations & Filings

Ticker · SBFM ISIN · US8677817004 LEI · 5299005Y64EHRQDQ2Q25 US Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2019-03-12 Regulatory Filings
Country US United States of America
Listing US SBFM

About Sunshine Biopharma Inc.

https://www.sunshinebiopharma.com/

Sunshine Biopharma Inc. is a pharmaceutical company engaged in the research, development, and commercialization of life-saving medicines. The company's primary focus is on various therapeutic areas, with a significant emphasis on oncology and antiviral treatments.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 12, 2019. It includes a Regulation FD Disclosure about a press release announcing the availability of a new product, Essential 9, on Amazon.ca. The document does not contain financial statements or detailed financial data, but rather announces a product launch event and includes a press release as an exhibit. The length is 3681 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication of financial results, management discussion, or audit information. Therefore, this document is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2019-03-12 English
INFORMATION STATEMENT
Proxy Solicitation & Information Statement Classification · 95% confidence The document is titled 'DEF 14C INFORMATION STATEMENT' and is filed pursuant to Section 14(c) of the Securities Exchange Act of 1934. It is a definitive information statement related to a shareholder action approving a reverse stock split of the company's common stock. The document discusses the details and effects of the reverse stock split, shareholder approval by written consent, and related corporate actions. It is not a proxy solicitation (explicitly states no proxy is requested), nor is it a full financial report or earnings release. The document is a communication to shareholders providing information about a corporate action requiring shareholder approval but does not contain financial statements or management discussion of financial results. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings or consents. The document is not an announcement of voting results (DVA), nor a regulatory filing of another type. Therefore, the correct classification is PSI with high confidence.
2019-01-31 English
INFORMATION STATEMENT
Proxy Solicitation & Information Statement Classification · 95% confidence The document is titled 'INFORMATION STATEMENT' and is filed on SEC Schedule 14C, which is used for information statements pursuant to Section 14(c) of the Securities Exchange Act of 1934. The content discusses a reverse stock split approved by the board and shareholders, detailing the terms, purpose, and effects of the reverse split. It explicitly states it is not a proxy solicitation and is being furnished to shareholders as written notice. The document is not a proxy statement, earnings release, or annual report, but rather an information statement related to a corporate action (reverse stock split). According to the filing definitions, Schedule 14C Information Statements are best classified under Proxy Solicitation & Information Statement (PSI), as they provide information to shareholders to inform or request votes for meetings or corporate actions. The document is substantive and not a mere announcement or certification, and it is not a full annual or interim report. Therefore, the appropriate classification is PSI with high confidence.
2018-11-28 English
QUARTERLY REPORT
Interim / Quarterly Report 9M 2018
2018-11-16 English
PRIMARY DOCUMENT
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25, which is a Notification of Late Filing submitted to the SEC. It specifically states it is related to a Form 10-Q for the quarterly period ended September 30, 2018. The document explains the reason for the delay in filing the 10-Q report and requests relief for the late filing. It does not contain the actual financial statements or substantive financial data of the 10-Q report itself, but rather is a notification about the delay in filing that report. According to the rules, such a notification is classified as a Regulatory Filing (RNS) because it is a compliance document related to filing deadlines and does not contain the report itself.
2018-11-14 English
RW
Regulatory Filings Classification · 100% confidence The document is a formal letter addressed to the SEC requesting the withdrawal of a Registration Statement on Form S-1. It references regulatory rules under the Securities Act and confirms that no securities were sold. The document is short (2068 characters) and is clearly an official withdrawal request rather than a financial report or detailed filing. It does not contain financial data, earnings, management discussion, or any report content. This fits the category of a Regulatory Filing (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2018-10-31 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.